FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 455 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... November 10, 2021 ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ November 22, 2018 Happy New Year From Our Team January 4, 2021 Longer Duration of Treatment with ICIs Associated with a Higher Rate... March 5, 2025 Load more HOT NEWS After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought Death Rates from Lung Cancer will Fall Overall in the EU... Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has... EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab
